• ERK, Mitochondrial Dynamics, and OGD/R Injury

  2026-09-09

  Yuan et al. identify an ERK–Drp1/Mfn2–autophagy axis that links mitochondrial fragmentation to neuronal injury after oxygen-glucose deprivation/reoxygenation. Their pharmacological, genetic, imaging, and functional data suggest that ERK inhibition protects SH-SY5Y cells by limiting Drp1-dependent fission and excessive autophagy, while also defining important limitations for interpreting TPA-based pathway activation.

• SB 225002: CXCR2 Assay Workflows

  2026-09-09

  SB 225002 provides a selective way to test whether CXCR2 drives IL-8- or GROα-dependent neutrophil trafficking without assuming that every IL-8 response is CXCR2-mediated. This guide translates recent MRSA extracellular-vesicle and oral cancer findings into practical migration, receptor-dissection, and troubleshooting workflows.

• AIBP–LRP2 Restricts CXCR4+ Collateral Growth

  2026-09-08

  Zhu et al. identify an AIBP–LRP2–HDL–miR-223 pathway that suppresses CXCR4-positive, stemlike capillary endothelial cells during collateral vessel formation. Their human–mouse evidence supports a two-phase model in which CXCR4-positive endothelial cells expand and subsequently acquire arterial characteristics, suggesting a mechanistically defined route for studying revascularization in peripheral artery disease.

• Dronedarone (Multaq) Research Workflow

  2026-09-07

  Build exposure-aware Dronedarone workflows for atrial fibrillation, atrial flutter, and cardiac ion-channel studies. This guide combines automated patch clamp, solvent control, therapeutic-exposure benchmarking, and troubleshooting to clarify whether KCa2 channels contribute to an observed phenotype.

• Peptidisc-Assisted Nanobody Multimerization

  2026-09-07

  The reference preprint introduces peptidisc-assisted hydrophobic clustering as a route to assemble nanobodies into soluble multimeric, bispecific, and autofluorescent polybodies. By coupling nanobodies to transmembrane segments and stabilizing the resulting hydrophobic associations with peptidiscs, the authors obtained avidity-enhanced binding to GFP and human serum albumin, suggesting a flexible alternative to tandem fusion and conventional cross-linking.

• Streptavidin-Cy3 for Barrier-Resolved Assays

  2026-09-05

  Streptavidin-Cy3 can convert biotinylated probes into spatial evidence for studies of deformable, magnetically guided biohybrid microrobots. This article explains how to distinguish localization, molecular engagement, and true biological access across tissue imaging and flow cytometry.

• Otilonium Bromide: From Receptor Probe to Translation

  2026-09-04

  A translational framework for using Otilonium Bromide to interrogate muscarinic cholinergic biology, improve assay interpretability, and distinguish pathway-level pharmacology from structure-based antiviral discovery.

• Sulfo-NHS-SS-Biotin: Practical Labeling Guide

  2026-09-04

  Sulfo-NHS-SS-Biotin enables aqueous labeling of accessible primary amines on proteins and intact-cell surfaces, followed by avidin or streptavidin-based capture and optional disulfide cleavage. It is not intended for intracellular labeling or storage as a prepared solution because the sulfo-NHS ester hydrolyzes rapidly.

• Bradykinin B2 Receptors and Ileal Peristalsis

  2026-09-03

  The reference study established that bradykinin inhibits the peristaltic reflex in isolated guinea pig ileum through B2, rather than B1, kinin receptors. Its pressure-threshold assay, selective agonists, and antagonist comparisons provide a useful pharmacological framework for dissecting receptor control of gastrointestinal motility.

• PEGylated PLGA Microspheres for Sustained Steroid Release

  2026-09-03

  Myers and Comolli developed PEGylated PLGA microspheres carrying hydrocortisone 17-butyrate and used release modeling to examine how surface modification changes corticosteroid delivery. The optimized formulation reached approximately 1.22 μm in diameter, achieved 71.98% entrapment efficiency, and reduced burst release while supporting diffusion-controlled release over three weeks.

• MOB1A/B Loss Rewires Intestinal Wnt–BMP/TGF-β Signaling

  2026-09-02

  Bae et al. show that intestinal epithelial MOB1A/B depletion disrupts homeostasis through simultaneous Wnt suppression and BMP/TGF-β activation, despite an initial increase in epithelial proliferation. Pharmacological inhibition partially restores secretory-cell differentiation but not intestinal stem-cell pools, revealing distinct pathway requirements for epithelial maintenance.

• Captopril Workflows for ACE and Bradykinin Research

  2026-09-02

  Captopril is more than an antihypertensive drug for blood pressure control: its defined ACE activity supports concentration-response, angiotensin pathway, and bradykinin-intersection experiments. This practical guide translates published ileum pharmacology into controlled assay designs while separating established evidence from testable oncology and gastrointestinal hypotheses.

• Gastric Cancer Assembloids for Drug Response Modeling

  2026-09-01

  A 2025 study developed patient-derived gastric cancer assembloids by combining matched tumor organoids with stromal cell subpopulations from the same tumor. The model reproduced tumor heterogeneity, altered transcriptomic states and drug responses relative to organoid monocultures, providing a more physiologically relevant framework for resistance studies and personalized treatment research.

• NHS-Biotin Workflows for Multimeric Protein Assays

  2026-09-01

  NHS-Biotin provides a compact, irreversible biotin tag for antibody, protein, and intracellular labeling workflows. Its utility extends from streptavidin-based detection and purification to studying peptidisc-stabilized nanobody assemblies without confusing labeling with the multimerization process itself.

• MLKL Polymerization Drives Lysosomal Permeabilization

  2026-08-31

  The reference study identifies lysosomal membrane permeabilization as a critical intermediate in MLKL-mediated necroptosis. Its experiments show that MLKL polymerization damages lysosomes, releases active cathepsins, and makes cathepsin B a major contributor to the proteolytic destruction that precedes cell death.

8571 records 1/572 page Next 12345 下5页 Last page